Theravance Unveils Separation Plans and Initiates Dividend As Q1 Loss Widens 81%

Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance (NASDAQ: THRX  ) , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two separate trading entities.

For the quarter, Theravance recorded net revenue of just $0.2 million, down from $1.3 million in the prior-year period. Vibativ product sales totaled $0.9 million and royalty revenue from the sale of Relvar and Breo Ellipta totaled $0.7 million. However, revenue was also offset by amortized expenses tied to intangible assets.

As you might have guessed, with a full lineup of clinical studies ongoing, Theravance's research and development and selling, general, and administrative expenses soared. R&D expenses rose to $43.4 million from $26.4 million in the prior year, while SG&A costs more than doubled to $22.8 million from $8.3 million.

Net loss for the quarter widened by 81% to $67.7 million, or $0.62 per share from $37.4 million, or $0.39 per share in the previous year.

Two additional developments dominated Theravance's report.

First, given Thervance's strong cash position of $430.8 million as of the end of the quarter, it plans to initiate a $0.25-per-quarter cash dividend. This would place a projected forward yield of 3.7% on Theravance based on today's closing price.

Secondly, Theravance set the course for its upcoming split into two companies: Royalty Management Co., consisting of its FDA-approved COPD assets and other collaborations under partnership with GlaxoSmithKline (NYSE: GSK  ) , and Theravance BioPharma, consisting of every other therapeutic indication in its pipeline. Shareholders on record as of May 15 will receive Theravance BioPharma shares in the form of dividend by June 2.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2946488, ~/Articles/ArticleHandler.aspx, 8/29/2015 2:08:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
THRX $13.82 Down +0.00 +0.00%
Theravance, Inc. CAPS Rating: ***
GSK $41.25 Up +0.04 +0.10%
GlaxoSmithKline CAPS Rating: ****